Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VATHOS
2024-513568-24-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of budesonide and formoterol in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Started Mar 2022; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-513568-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513568-24-00.